Late-night salivary cortisol and cortisone should be the initial screening test for Cushing's syndrome.
Cushing’s syndrome
salivary cortisol
salivary cortisone
screening
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
01 Jul 2022
01 Jul 2022
Historique:
received:
18
05
2022
accepted:
07
06
2022
pubmed:
8
6
2022
medline:
8
6
2022
entrez:
7
6
2022
Statut:
epublish
Résumé
Endogenous Cushing's syndrome (CS) poses considerable diagnostic challenges. Although late-night salivary cortisol (LNSC) is recommended as a first-line screening investigation, it remains the least widely used test in many countries. The combined measurement of LNSC and late-night salivary cortisone (LNS cortisone) has shown to further improve diagnostic accuracy. We present a retrospective study in a tertiary referral centre comparing LNSC, LNS cortisone, overnight dexamethasone suppression test, low-dose dexamethasone suppression test and 24-h urinary free cortisol results of patients investigated for CS. Patients were categorised into those who had CS (21 patients) and those who did not (33 patients). LNSC had a sensitivity of 95% and a specificity of 91%. LNS cortisone had a specificity of 100% and a sensitivity of 86%. With an optimal cut-off for LNS cortisone of >14.5 nmol/L the sensitivity was 95.2%, and the specificity was 100% with an area under the curve of 0.997, for diagnosing CS. Saliva collection is non-invasive and can be carried out at home. We therefore advocate simultaneous measurement of LNSC and LNS cortisone as the first-line screening test to evaluate patients with suspected CS.
Identifiants
pubmed: 35671282
doi: 10.1530/EC-22-0050
pii: EC-22-0050
pmc: PMC9254321
doi:
pii:
Types de publication
Journal Article
Langues
eng